Shares of Veeva Systems Inc. (NYSE:VEEV – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-five brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and fifteen have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $256.52.
Several brokerages have recently commented on VEEV. Morgan Stanley boosted their target price on shares of Veeva Systems from $195.00 to $201.00 and gave the company an “underweight” rating in a research report on Thursday, March 6th. Robert W. Baird boosted their price objective on shares of Veeva Systems from $283.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, March 6th. StockNews.com raised Veeva Systems from a “hold” rating to a “buy” rating in a report on Monday, February 17th. Mizuho assumed coverage on Veeva Systems in a report on Wednesday, December 4th. They set an “outperform” rating and a $275.00 price target for the company. Finally, JPMorgan Chase & Co. upped their price objective on Veeva Systems from $218.00 to $249.00 and gave the stock a “neutral” rating in a research report on Thursday, March 20th.
Check Out Our Latest Stock Analysis on VEEV
Institutional Trading of Veeva Systems
Veeva Systems Stock Down 1.4 %
VEEV stock opened at $234.10 on Friday. Veeva Systems has a 52 week low of $170.25 and a 52 week high of $258.93. The business has a 50-day simple moving average of $231.62 and a 200 day simple moving average of $222.87. The company has a market cap of $38.01 billion, a PE ratio of 57.80, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88.
Veeva Systems Company Profile
Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.
Featured Stories
- Five stocks we like better than Veeva Systems
- Investing In Preferred Stock vs. Common Stock
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Using the MarketBeat Dividend Tax Calculator
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.